Related Experiment Video
Updated: May 14, 2026

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study
Jianlei Hao1, Kun Wang, Yuejuan Shao
1Department of Pain Relief, Cancer Institute and Hospital of Tianjin Medical University, Key Laboratory of Cancer Prevention and Treatment, Tianjin, PR China.
Objective:
To compare the treatment effect reducing cancer-related multiple breakthrough pain (BTP) between immediate release morphine sulfate (IRMS) and flurbiprofen axetil.
Methods:
Eligible patients with refractory BTP were divided into two groups; the control group received IRMS for rescue care; the flurbiprofen group received intravenous flurbiprofen axetil. Patients were asked to assess the effect of rescue medication on their most severe pain.
Results:
The study assessed 217 patients, 122 in the control group and 95 in the flurbiprofen group. The average time to meaningful pain relief following the administration of rescue medication in the two groups was 27.3 minutes (control group) and 16.0 minutes (flurbiprofen group, P<0.01). A significant reduction in pain intensity was found in both groups; the average visual analog scale (VAS) score was reduced from 7.8 to 3.0 in the control group and from 7.9 to 2.2 in the flurbiprofen group (P<0.01).
Conclusion:
Flurbiprofen axetil can relieve BTP quickly and effectively.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Treatment Resistant Cancers
Analgesia and Pain Management
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...

